Abbott Laboratoriess in-depth stock price analysis indicates that the stock price has rallied 7.28% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -0.56% . Looking at the past 52 week period, the stock price is up at 15.11% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Abbott Laboratories has a negative value of -8.18 compared to overall market performance. Abbott Laboratories (NYSE:ABT) has tumbled 0.09% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 4.42% in the last four weeks. The stocks have underperformed the S&P 500 by 0.9% during the past week but Abbott Laboratories (NYSE:ABT) it has outperformed the index in 4 weeks by 2.55%.
Abbott Laboratories (NYSE:ABT) : On Friday heightened volatility was witnessed in Abbott Laboratories (NYSE:ABT) which led to swings in the share price. The stock opened for trading at $42.74 and hit $42.8 on the upside , eventually ending the session at $42.74, with a gain of 0.47% or 0.2 points. The heightened volatility saw the trading volume jump to 3,692,381 shares. The 52-week high of the share price is $45.79 and the company has a market cap of $73,778 million. The 52-week low of the share price is at $36.02 .
Abbott Laboratories Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.65 EPS for the quarter. Analyst had a consensus estimate of $0.65. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5375.38 million. The companys revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Abbott Laboratories was Reiterated by RBC Capital Mkts on Jan 26, 2017 to Outperform, Lowers Price Target to $ 46 from a previous price target of $48 .
Company has reported several Insider transactions to the SEC, on Feb 2, 2017, Stephen R Fussell (Executive Vice President) purchased 12,200 shares at 40.77 per share price.On Feb 2, 2017, Heather L Mason (Executive Vice President) sold 35,700 shares at 40.77 per share price.On Dec 21, 2016, Brian J Blaser (Executive Vice President) purchased 15,580 shares at 38.44 per share price.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.